Discover October 2024's Promising US Penny Stocks

In This Article:

As the U.S. markets experience mixed results with the S&P 500 and Dow Jones snapping their six-week winning streaks, investors are keenly observing economic data and earnings reports for further insights. In this context, penny stocks—often representing smaller or newer companies—remain a compelling area of interest due to their potential for growth and affordability. Despite being considered a niche investment category, these stocks can offer significant opportunities when they possess strong financial health, making them worthy of consideration in today's market landscape.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.78982

$5.74M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.12

$512.97M

★★★★★★

RLX Technology (NYSE:RLX)

$1.61

$2.05B

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.43

$148.35M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.59

$52.47M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

MIND C.T.I (NasdaqGM:MNDO)

$1.88

$39.06M

★★★★★★

Better Choice (NYSEAM:BTTR)

$1.68

$2.78M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.10

$98.93M

★★★★★☆

Click here to see the full list of 760 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Tiziana Life Sciences

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tiziana Life Sciences Ltd is a biotechnology company that focuses on discovering and developing molecules for treating human diseases in oncology and immunology in the United States, with a market cap of $101.47 million.

Operations: Tiziana Life Sciences Ltd does not report any revenue segments.

Market Cap: $101.47M

Tiziana Life Sciences, with a market cap of US$101.47 million, operates as a pre-revenue biotech entity focused on oncology and immunology. Despite its unprofitability and volatile share price, the company has maintained shareholder value without significant dilution over the past year. Recent leadership changes include appointing Ivor Elrifi as CEO to strengthen strategic direction. Tiziana has regained Nasdaq compliance for its listing requirements but faces short-term financial challenges with assets not fully covering liabilities and only a brief cash runway available. The company recently withdrew a US$50 million equity offering but remains debt-free, potentially mitigating some financial risks.